HC Wainwright Comments on Vera Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:VERA)
HC Wainwright Comments on Vera Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:VERA)
Vera Therapeutics, Inc. (NASDAQ:VERA – Get Rating) – Investment analysts at HC Wainwright issued their FY2027 earnings per share estimates for shares of Vera Therapeutics in a research report issued to clients and investors on Wednesday, January 4th. HC Wainwright analyst E. Arce forecasts that the company will post earnings per share of ($0.49) for the year. HC Wainwright has a "Buy" rating and a $15.00 price target on the stock. The consensus estimate for Vera Therapeutics' current full-year earnings is ($3.08) per share.
维拉治疗公司(纳斯达克代码:VERA-GET评级)-HC Wainwright的投资分析师在1月4日星期三发布给客户和投资者的一份研究报告中发布了他们对Vera治疗公司股票2027财年每股收益的估计。HC Wainwright分析师E.Arce预测,该公司今年的每股收益将为0.49美元。HC Wainwright对该股的评级为买入,目标价为15.00美元。对Vera Treateutics目前全年收益的普遍估计为每股3.08美元。
Vera Therapeutics (NASDAQ:VERA – Get Rating) last released its quarterly earnings results on Wednesday, November 9th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.19).
维拉治疗公司(纳斯达克:维拉-GET评级)最近一次发布季度收益报告是在11月9日星期三。该公司公布本季度每股收益(EPS)为0.91美元,低于分析师一致预期的0.72美元和0.19美元。
Vera Therapeutics Trading Down 2.1 %
维拉治疗公司股价下跌2.1%
Shares of VERA stock opened at $5.48 on Thursday. The business's 50 day moving average is $17.14 and its two-hundred day moving average is $17.93. Vera Therapeutics has a twelve month low of $5.20 and a twelve month high of $24.98. The company has a market capitalization of $151.57 million, a P/E ratio of -1.85 and a beta of -0.02. The company has a current ratio of 7.85, a quick ratio of 7.85 and a debt-to-equity ratio of 0.05.
周四,维拉的股票开盘报5.48美元。该业务的50日移动均线切入位在17.14美元,200日移动均线切入位在17.93美元。Vera Treateutics的12个月低点为5.20美元,12个月高位为24.98美元。该公司市值为1.5157亿美元,市盈率为-1.85,贝塔系数为-0.02。该公司的流动比率为7.85,速动比率为7.85,债务权益比率为0.05。
Institutional Investors Weigh In On Vera Therapeutics
机构投资者对维拉治疗公司的看法
A number of institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank purchased a new stake in shares of Vera Therapeutics in the first quarter worth about $34,000. Swiss National Bank purchased a new stake in shares of Vera Therapeutics in the second quarter worth about $472,000. Bank of Montreal Can purchased a new stake in shares of Vera Therapeutics in the second quarter worth about $1,411,000. Alps Advisors Inc. purchased a new stake in shares of Vera Therapeutics in the second quarter worth about $219,000. Finally, Polar Asset Management Partners Inc. boosted its position in shares of Vera Therapeutics by 77.8% in the third quarter. Polar Asset Management Partners Inc. now owns 523,400 shares of the company's stock worth $11,154,000 after buying an additional 229,100 shares during the period. Hedge funds and other institutional investors own 88.64% of the company's stock.
一些机构投资者最近增持或减持了该公司的股份。合并银行在第一季度购买了Vera Treateutics价值约3.4万美元的新股。瑞士国家银行在第二季度购买了Vera治疗公司的新股份,价值约472,000美元。蒙特利尔银行可以在第二季度购买维拉治疗公司价值约1,411,000美元的新股份。Alps Advisors Inc.在第二季度购买了价值约21.9万美元的Vera Treateutics新股。最后,Polar Asset Management Partners Inc.在第三季度将其在Vera Treateutics的股票头寸增加了77.8%。Polal Asset Management Partners Inc.在此期间又购买了229,100股,目前持有523,400股该公司股票,价值11,154,000美元。对冲基金和其他机构投资者持有该公司88.64%的股票。
Insider Activity
内幕活动
In other news, insider Joanne Curley sold 2,212 shares of Vera Therapeutics stock in a transaction on Friday, December 16th. The stock was sold at an average price of $19.49, for a total value of $43,111.88. Following the completion of the sale, the insider now owns 26,821 shares of the company's stock, valued at $522,741.29. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 14,091 shares of company stock valued at $261,974 over the last quarter. Company insiders own 43.10% of the company's stock.
其他消息,内部人士乔安妮·柯利在12月16日(星期五)的一笔交易中出售了2212股Vera治疗公司的股票。这只股票的平均售价为19.49美元,总价值为43,111.88美元。出售完成后,这位内部人士现在拥有26,821股该公司股票,价值522,741.29美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过美国证券交易委员会网站。在上个季度,内部人士总共出售了14,091股公司股票,价值261,974美元。公司内部人士持有该公司43.10%的股份。
About Vera Therapeutics
关于维拉治疗公司
(Get Rating)
(获取评级)
Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
维拉治疗公司是一家临床阶段生物技术公司,专注于开发美国严重免疫疾病患者的治疗方法并将其商业化。它的主要候选产品是atacicept,这是一种自我皮下注射的融合蛋白,目前正处于针对免疫球蛋白A肾病患者的IIb期临床试验。
Recommended Stories
推荐故事
- Get a free copy of the StockNews.com research report on Vera Therapeutics (VERA)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
- 免费获取StockNews.com关于VERA治疗(VERA)的研究报告
- MarketBeat:回顾中的一周01/02-01/06
- 为什么CrowdStrike的股价举步维艰?
- 2023年四只被低估的医疗保健股票
- WWE股票:文斯·麦克马洪想要重返节目
- NVIDIA正在触底,但现在还不能买入
Receive News & Ratings for Vera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《维拉治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Vera Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。